OBJECTIVE： To systematically review therapeutic efficacy of Haikun shenxi capsule in the treatment of chronic renal failure （CRF）. METHODS： Retrieved from Central， PubMed， EMBase， CJFD， CBM， VIP and Wanfang database， randomized clinical trials （RCTs） about Haikun shenxi capsule combined with routine treatment （trial group）vs. single routine treatment （control group） in the treatment of CRF were collected. Meta-analysis was performed by Rev Man 5.3 software after screening literature， extracting data and evaluating quality by using risk bias evaluation of Cochrane collaboration network. RESULTS： A total of 10 RCTs were included eventually， involving 704 patients. The results of analysis showed that compared to general therapy， Haikun shenxi capsule could improve total effective rate [RR＝4.42，95％CI（2.70，7.22），P＜0.001]， and could reduce SCr[MD＝－140.37，95％CI（－191.72，－89.03），P＜0.001]， BUN[MD＝－5.49，95％CI（－8.36，－2.63），P＜0.001] and 24 h-Upro[MD＝－0.43，95％CI（－0.62，－0.23），P＜0.001]，with statistical significance. CONCLUSIONS： The clinical efficacy of Haikun shenxi capsule in the treatment of CRF is good and significantly improve related indexes of renal function.